RIPK3 and neoplasm: Early on-treatment, there was an increase in intratumoral expression of GSDMD, RIPK3, and MLKL, genes associated with pyroptosis/necroptosis,56 forms of inflammatory cell death that drive release of antigens from tumor cells as well as release of inflammatory factors such as IL-1β and IL-18,56 leading to potentiation of anti-tumor immunity.46